{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bells-palsy/management/management/","result":{"pageContext":{"chapter":{"id":"580ab30d-9576-59c4-aeb3-9e8ab7cf50f6","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 5e07e8f0-aed8-454b-94fb-603e34bb3def --><h2>Scenario: Management of Bell's palsy</h2><!-- end field 5e07e8f0-aed8-454b-94fb-603e34bb3def -->","summary":"Covers the management of Bell's palsy in primary care.","htmlStringContent":"<!-- begin item 9b59e00f-e921-4450-9c56-0e7af606cc87 --><!-- begin field 76357fa5-ef65-4c3c-b743-acbc01563667 --><p>From age 16 years onwards.</p><!-- end field 76357fa5-ef65-4c3c-b743-acbc01563667 --><!-- end item 9b59e00f-e921-4450-9c56-0e7af606cc87 -->","topic":{"id":"6fbcd4fc-1e27-559d-a207-7d4c6e8a54c5","topicId":"9c711b5e-c5b5-4f3c-b945-03cdc7807c10","topicName":"Bell's palsy","slug":"bells-palsy","lastRevised":"Last revised in May 2019","chapters":[{"id":"4766eebb-2309-5052-95ac-c1caa9148c74","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db32d671-3f2b-5a87-b519-7669b8264c9a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"f0f94c71-8863-5e80-afaf-ce82a7ff02e6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"2d1a280f-83d3-5834-8106-967a1775e6fc","slug":"changes","fullItemName":"Changes"},{"id":"1aaff76b-872b-5b85-92e8-a5f0b5c67456","slug":"update","fullItemName":"Update"}]},{"id":"fc61bdf1-ca84-5251-917a-fbaab7117880","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c98cd005-6000-5418-99a1-ac342ad3b4e7","slug":"goals","fullItemName":"Goals"},{"id":"876cef67-9108-5739-9141-704b04759856","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ff255679-9bc9-5a91-a85c-2625d677c680","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"10d81db5-096a-5c90-b0ee-3de71dabf027","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f1bb6854-fede-5e16-b78b-44afca38d202","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"e38894d6-3084-5df2-9413-00eb027d1163","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7e6b973b-b704-56dc-a55c-af9fdc05661f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"915bc3f0-4245-580a-9c92-09bd021d7cd5","slug":"definition","fullItemName":"Definition"},{"id":"3dea1016-6501-5565-a564-2fcc8ff4b4cc","slug":"causes","fullItemName":"Causes"},{"id":"f6fd8c55-4dda-56c3-803c-9b39e31756e4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"89fcff44-16b1-5c34-934f-6f1e9fa581a3","slug":"complications","fullItemName":"Complications"},{"id":"ce4aa652-88c1-54de-9710-b2e99d125c14","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"750af3ec-c1d1-50ef-8c31-adbaa6bb1d66","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"05b003ce-5eeb-5a69-90cb-06156a2d161a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"5149e954-facb-51cd-933c-ca1a6a347e45","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"585d604e-eaf7-502b-ac0a-b095aa5bbe2f","fullItemName":"Management","slug":"management","subChapters":[{"id":"580ab30d-9576-59c4-aeb3-9e8ab7cf50f6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"432dede6-8464-590b-a61f-3171fc8e7cd3","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"0658bd57-de66-5dc2-8f3e-306129a919cc","slug":"prescribing-corticosteroids","fullItemName":"Prescribing corticosteroids"}]},{"id":"678ae58e-9085-5f8f-8954-bf1b7cf37ec3","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"90857d48-d611-53bc-b3ea-5ed10d7969ad","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"02482d74-322e-5b12-91be-457763d1565f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f0e77799-ffea-5a5c-89ab-ab66837415c6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"59a234a3-506d-5e44-80fc-95608abc0551","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"2f1ea24b-e581-527f-b00d-3edb42411a27","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"9860105b-6cd3-590e-8b47-75b5ae738fa6","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"142db3ba-6dda-5137-b241-8a8c353d1ebb","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"585d604e-eaf7-502b-ac0a-b095aa5bbe2f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"478a3d76-7675-5f59-b5b0-43ee416520eb","slug":"advice","fullItemName":"Advice","depth":3,"htmlHeader":"<!-- begin field 2f48961b-5a7c-46d8-ba96-6c73a7b4f0bf --><h3>What advice can I give people with Bell's palsy?</h3><!-- end field 2f48961b-5a7c-46d8-ba96-6c73a7b4f0bf -->","summary":null,"htmlStringContent":"<!-- begin item 0a314a25-b6e8-4313-b568-228c58960db7 --><!-- begin field f6594eaa-6ee9-4774-a49b-d4520d027891 --><ul><li><strong>Reassure the person that the prognosis is good.</strong> Most people with Bell's palsy make a full recovery within 3–4 months. Advise that:<ul><li>It is important to keep the affected eye lubricated. Lubricating eye drops should be used frequently during the day and eye ointment used at night.<ul><li>A large range of tear replacement and ocular lubricant products are available on prescription or over the counter. For a complete list of products available in the UK, see the British National Formulary (<a data-hyperlink-id=\"f9ba215b-af6e-4eea-95ef-a93601035c08\" href=\"https://bnf.nice.org.uk/\">BNF</a>).</li></ul></li><li>If they are unable to close the eye at bedtime, they should tape it closed using microporous tape.</li><li>Wearing sunglasses when outdoors, can help protect the eye. </li><li>Situations that may cause eye irritation such as swimming and dusty environments should be avoided if possible. </li><li>If they experience eye irritation, pain, or vision changes, they should seek immediate medical advice. </li></ul></li><li><strong>If facial weakness or paralysis affects eating,</strong> suggest using a straw for liquids and advise eating soft foods.</li><li><strong>Offer the person written advice,</strong> such as information on <a data-hyperlink-id=\"4778a670-539d-4d42-8e0c-a93601035c90\" href=\"https://www.nhs.uk/conditions/bells-palsy/\">Bell's palsy</a> available from <a data-hyperlink-id=\"f9a92bbb-af30-4464-b2b3-a93601035f2f\" href=\"https://www.nhs.uk/pages/home.aspx\">NHS </a><a href=\"https://www.nhs.uk/conditions/\" data-hyperlink-id=\"2c80558b-871e-4751-a873-aa5600d04dd5\">A-Z</a>.</li></ul><!-- end field f6594eaa-6ee9-4774-a49b-d4520d027891 --><!-- end item 0a314a25-b6e8-4313-b568-228c58960db7 -->","subChapters":[{"id":"413dcf47-e8ba-5dde-9709-608439caf84e","slug":"basis-for-recommendation-38c","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 67a03016-79a2-4ee0-b70f-c7d88bf10c66 --><h4>Basis for recommendation</h4><!-- end field 67a03016-79a2-4ee0-b70f-c7d88bf10c66 -->","summary":null,"htmlStringContent":"<!-- begin item 38c9b3c9-7eea-452a-86f7-5f1e9729d81c --><!-- begin field fed2b8d9-b0c5-4493-8819-6e511b5e5993 --><h5>Reassurance about the prognosis.</h5><ul><li>This recommendation is based on an American Academy of Otolaryngology - Head and Neck Surgery (AAO-HNS) clinical practice guideline on Bell's palsy that discusses the benefits of giving people information about recovery and the likely time course of their symptoms.<strong> </strong>CKS has based the prognostic information on data discussed in this guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>]. </li></ul><h5>Advice about eye care</h5><ul><li>In the absence of specific evidence for people with Bell's palsy, expert consensus in AAO-HNS and Canadian clinical practice guidelines advocates eye care for people with incomplete eye closure to reduce the risk of damage to the eye from foreign bodies, corneal abrasions, and exposure keratitis which may result in loss of vision [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>]. </li><li>Specific advice on eye care measures is based on expert opinion in review articles [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Zandian et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Eviston et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Masterson et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Phan et al, 2016</a>]. Eye drops hydrate the eye and prevent moisture loss, but need to be applied frequently. Ointments are beneficial in that they prevent moisture loss well and need applying less often, but can blur vision. Taping can be a useful strategy at night, but must be effectively carried out [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>].  </li></ul><h5>Advice on eating</h5><ul><li>This recommendation is based on expert opinion in a review article on the basis that these measures minimise the risk of oral incontinence (from loss of sphincter function of the orbicularis oris) and damage to the inside of the mouth from chewing [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Eviston et al, 2015</a>]. </li></ul><h5>Offering written information</h5><ul><li>This recommendation is pragmatic, and is based on what CKS considers to be good clinical practice.</li></ul><!-- end field fed2b8d9-b0c5-4493-8819-6e511b5e5993 --><!-- end item 38c9b3c9-7eea-452a-86f7-5f1e9729d81c -->","subChapters":[]}]},{"id":"28d2977c-e1e6-574f-a02f-08d896e039db","slug":"treatment","fullItemName":"Treatment","depth":3,"htmlHeader":"<!-- begin field f8908ec4-477c-4509-9d34-513d4cb4c8d0 --><h3>How should I manage Bell's palsy?</h3><!-- end field f8908ec4-477c-4509-9d34-513d4cb4c8d0 -->","summary":null,"htmlStringContent":"<!-- begin item 541c5883-4a26-4f5c-8e3e-fd71dd9e2268 --><!-- begin field 1c36be1d-eebc-48c6-9183-74d40aa716d7 --><ul><li><strong>For people presenting within 72 hours of the onset of symptoms, consider prescribing prednisolone.</strong> There is no consensus regarding the optimum dosing regimen, but options include:<ul><li>Giving 50 mg daily for 10 days <em>or</em></li><li>Giving 60 mg daily for five days followed by a daily reduction in dose of 10 mg (for a total treatment time of 10 days) if a reducing dose is preferred.</li></ul></li><li><strong>Antiviral treatments alone are not recommended. </strong><ul><li>Antiviral treatment in combination with a corticosteroid may be of small benefit, but seek specialist advice if this is being considered.</li></ul></li></ul><!-- end field 1c36be1d-eebc-48c6-9183-74d40aa716d7 --><!-- end item 541c5883-4a26-4f5c-8e3e-fd71dd9e2268 -->","subChapters":[{"id":"1ec00c1b-4476-50cb-bbeb-8e4f43a50098","slug":"basis-for-recommendation-e7e","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e78f6e52-7e5a-4acc-be79-e22ce59560dd --><h4>Basis for recommendation</h4><!-- end field e78f6e52-7e5a-4acc-be79-e22ce59560dd -->","summary":null,"htmlStringContent":"<!-- begin item e7e7c327-11bc-4bb5-866e-3a3d3570f3c7 --><!-- begin field 098fc856-53ff-4e27-a279-71776eba725f --><h5>Oral corticosteroids</h5><ul><li>The recommendation to prescribe oral corticosteroids within 72 hours of symptom onset for people with Bell's palsy aged 16 years and older is based on a clinical practice guideline from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>], an evidence-based guideline update from the American Academy of Neurology [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gronseth et al, 2012</a>], and a Canadian clinical practice guideline aimed at primary care physicians [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>]. The dosing schedule is influenced by the guideline development group of the AAO-HNS clinical practice guideline which based its suggested regimens on those used in two large randomized controlled trials (n = 551, n = 829) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Sullivan et al, 2007</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Engstrom et al, 2008</a>]. </li><li>A Cochrane systematic review (search date March 2016) showed significant benefits with corticosteroid treatment for Bell's palsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Madhok et al, 2016</a>].  <ul><li>The main outcome measure was incomplete recovery of facial motor function or residual weakness. Seven trials (n = 895) showed that, in the corticosteroid group, 17% had incomplete recovery of motor function compared with 28% in the control group of people receiving no effective treatment for Bell's palsy (risk ratio [RR] 0.63, 95% CI 0.50 to 0.80). The number needed to treat with corticosteroids to prevent one case of incomplete recovery was 10.</li><li>Other outcome measures were:<ul><li>Reduction in cosmetically disabling sequelae after 6 months. Low-quality evidence from two trials (n = 75) showed a similar effect with corticosteroid treatment compared with placebo (RR 0.96, 95% CI 0.40 to 2.29).</li><li>Motor synkinesis (involuntary facial movement) and crocodile tears. Three moderate-quality trials (n = 485) identified a reduction in motor synkinesis in the corticosteroid group (RR 0.64, 95% CI 0.45 to 0.91).</li></ul></li><li>In terms of adverse effects, data from three trials (n = 715) found no significant difference between the corticosteroid and placebo groups (RR 1.04, 95% CI 0.71 to 1.51).</li></ul></li></ul><h5>Antiviral treatment alone</h5><ul><li>Oral antiviral treatment alone is not recommended for new-onset Bell's palsy by AAO-HNS clinical practice guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>]<strong> </strong>and a Canadian clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>]. <strong> </strong></li><li>Antiviral drugs alone are not recommended because there is evidence that, when compared with placebo, they do not provide significant benefit in terms of complete recovery from Bell's palsy:<ul><li>A Cochrane systematic review on antiviral treatment for Bell's palsy (search date October 2014) found no benefit for antivirals alone compared with placebo in terms of incomplete recovery (n = 658; RR 1.10, 95% CI 0.87 to 1.40). There was also a significant benefit in a sample size of 768 people for those receiving corticosteroids alone compared with antivirals alone (RR 2.82, 95% CI 1.09 to 7.32) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gagyor et al, 2015</a>]. </li><li>In terms of motor synkinesis or 'crocodile tears', evidence from two trials (n = 472) showed fewer sequelae with corticosteroids than with antiviral treatment (RR 1.52, 95% CI 1.08 to 2.12) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gagyor et al, 2015</a>].  </li><li>In terms of adverse effects, low-quality evidence from three trials (n = 1528) showed no significant increase for antivirals compared with placebo or corticosteroids [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gagyor et al, 2015</a>].  </li></ul></li></ul><h5>Antiviral treatment combined with corticosteroids</h5><ul><li>Combined corticosteroid and antiviral treatment is not routinely recommended for people with Bell's palsy, because there is insufficient evidence to support its use compared with corticosteroids alone.</li><li>A Cochrane systematic review (search date October 2014) studied the use of combined corticosteroid and antiviral treatment for Bell's palsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gagyor et al, 2015</a>]:  <ul><li>In terms of incomplete recovery, when compared with corticosteroids alone, low-quality evidence suggests combined corticosteroid and antiviral treatment provide a significant benefit (RR 0.61, 95% CI 0.39 to 0.97, n = 1315). In people with severe symptoms, low-quality evidence indicated the rate of incomplete recovery at month six was reduced in the combined corticosteroid and antiviral group compared with corticosteroids alone (RR 0.64, 95% CI 0.41 to 0.99, n = 478).</li><li>For the outcome of motor synkinesis or 'crocodile tears', data from two moderate-quality trials (n = 469) showed a significant benefit of combined corticosteroid and antiviral treatment compared with corticosteroids and placebo for long-term sequelae (RR 0.56, 95% CI 0.36 to 0.87).</li><li>The Cochrane authors noted the low-quality of the evidence of benefit with combined antiviral and corticosteroid treatment in terms of incomplete recovery and suggested further investigation may be justified. There was high heterogeneity between the trials and wide confidence intervals indicating the potential for very little effect, in addition to a risk of bias.</li></ul></li><li>Published guidelines differ in their recommendations on combined corticosteroid and antiviral treatment.<ul><li>A Canadian clinical practice guideline advises not to combine corticosteroids and antiviral treatment for people with mild to moderate severity Bell's palsy, having calculated a number needed to treat for one fewer episode of unsatisfactory facial recovery of 100, but suggests their use if there is severe to complete paresis on the basis of calculating a number needed to treat of 14 in this group [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>]. </li><li>The AAO-HNS guideline development group gives clinicians the option of offering antiviral treatment in addition to oral corticosteroids within 72 hours for people with Bell's palsy, on the basis that there is a small potential improvement in the function of the facial nerve, while acknowledging that there is no proven benefit from large, high-quality clinical trials [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>].  </li><li>The guideline development subcommittee of the American Academy of Neurology concluded that, for people with new-onset Bell's palsy, combination treatment with corticosteroids and antivirals should be offered because of the possibility of a modest improvement in recovery compared with corticosteroids alone. They noted, however, that any potential benefit is small and not well established [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gronseth et al, 2012</a>].  </li></ul></li><li>Although the risks and adverse effects of antiviral treatment are minimal [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Albers and Tamang, 2014</a>], because of the lack of UK guidelines, low-quality evidence and conflicting recommendations between existing clinical practice guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gagyor et al, 2015</a>], uncertainty about the optimal antiviral drug and dosing regimen [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Phan et al, 2016</a>], possibility that the potential benefits may be small (combination treatment may not increase the probability of facial function improvement by more than 7%) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Gronseth et al, 2012</a>], and cost of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>], CKS recommends seeking specialist advice if combination treatment is being considered.</li></ul><h5>Physical therapy</h5><ul><li>CKS was unable to make a recommendation on physical therapy for Bell's palsy because of a lack of evidence to support its use. The AAO-HNS and consensus Canadian clinical practice guidelines also found insufficient consistent evidence on which to make a recommendation regarding physical therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>]. <strong> </strong><ul><li>A Cochrane systematic review of physical therapy for Bell's palsy (search date February 2011) discussed twelve studies [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Teixeira et al, 2011</a>].<ul><li>Therapies studied included electrical stimulation, exercises, massage, infrared treatment, and physical therapy with acupuncture.</li><li>No high-quality evidence was identified, so it is difficult to draw any conclusions. Low-quality evidence suggests that facial exercises may reduce sequelae in acute cases, but the authors discussed the need to confirm this with good-quality randomized controlled trials.</li></ul></li><li>A subsequent review also found insufficient good-quality evidence on which to base firm conclusions on the role of physical therapy combined with standard drug treatment in the management of Bell's palsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Ferreira et al, 2015</a>].  </li></ul></li></ul><!-- end field 098fc856-53ff-4e27-a279-71776eba725f --><!-- end item e7e7c327-11bc-4bb5-866e-3a3d3570f3c7 -->","subChapters":[]}]},{"id":"1c78f425-875a-5e35-81f2-9a17446860eb","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 26936ef5-ce8c-4ba8-ac4e-146a8f5f999e --><h3>When should I refer to secondary care?</h3><!-- end field 26936ef5-ce8c-4ba8-ac4e-146a8f5f999e -->","summary":null,"htmlStringContent":"<!-- begin item 492868f6-91eb-4d4c-a1ff-15a775c712c8 --><!-- begin field 6f3a4915-9718-4baa-8378-51f236f5bc53 --><ul><li><strong>Refer urgently to an appropriate specialist people with facial nerve palsy and:</strong><ul><li>Worsening of existing neurologic findings, or new neurologic findings.</li><li>Features suggestive of an upper motor neurone cause (for example limb paresis, facial paraesthesia, other cranial nerve involvement, postural imbalance).</li><li>Features suggestive of cancer (for example, gradual onset of symptoms, persistent facial paralysis for more than 6 months, pain in the distribution of the facial nerve, head or neck lesion suggestive of cancer, history of head and neck cancer, hearing loss on the affected side). </li><li>Systemic or severe local infection.</li><li>Trauma.</li></ul></li><li><strong>Refer to a facial nerve specialist (for example, a neurologist or ear, nose, and throat specialist)</strong> if there is doubt about the diagnosis or a person with Bell's palsy has:<ul><li>No improvement after 3 weeks of treatment. </li><li>Consider referring adults with Bell's palsy who have developed symptoms of aberrant reinnervation (including gustatory sweating or jaw-winking) 5 months or more after the onset of Bell's palsy for neurological assessment and possible treatment.</li><li>Any <a class=\"topic-reference internal-reference\" href=\"/topics/bells-palsy/diagnosis/diagnosis/\">atypical features</a>. <strong> </strong></li></ul></li><li><strong>Refer to an ophthalmologist </strong>if the person has eye symptoms (for example, pain, irritation, or itch).  </li><li><strong>Consider referral for further support or counselling</strong> if there are emotional consequences of persistent facial paralysis or paresis.</li></ul><!-- end field 6f3a4915-9718-4baa-8378-51f236f5bc53 --><!-- end item 492868f6-91eb-4d4c-a1ff-15a775c712c8 -->","subChapters":[{"id":"5255caa5-55c3-5195-aad4-78697885bd5a","slug":"basis-for-recommendation-256","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e0bc6b67-794c-4088-8ac8-d85b72a0c594 --><h4>Basis for recommendation</h4><!-- end field e0bc6b67-794c-4088-8ac8-d85b72a0c594 -->","summary":null,"htmlStringContent":"<!-- begin item 256e1f8a-88b2-4f59-8b52-6b7e31d009c7 --><!-- begin field b0addfe0-6ea7-438b-b794-74820e347897 --><p>The NICE guideline on Suspected Neurological Conditions: recognition and referral [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">NICE, 2019</a>], agreed that uncomplicated Bell's palsy can be diagnosed and managed in primary care. They thought it important that people with this condition know that recovery time can vary and that recovery might not be complete. Referral for specialist treatment can be beneficial for people who develop troublesome symptoms after recovering from Bell's palsy.</p><h5>Urgent referral</h5><ul><li>This recommendation is based on US and Canadian clinical practice guidelines [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>], and expert opinion in a practice pointer article on the assessment and management of facial nerve palsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Masterson et al, 2015</a>]. Apart from Bell's palsy there are many other conditions that can cause facial weakness and paralysis and should be excluded, such as stroke, brain tumours, tumours of the facial nerve or parotid glands, and systemic and infectious diseases<strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Glass and Tzafetta, 2014b</a>].</li></ul><h5>Referral to a facial nerve specialist</h5><ul><li>This recommendation is based on a US clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>]<strong> </strong>and review articles on general practice approaches to Bell's palsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Glass and Tzafetta, 2014a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Phan et al, 2016</a>] and management of facial palsy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Stew and Williams, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Masterson et al, 2015</a>].  <ul><li>A Canadian clinical practice guideline and review articles recommend investigation, including imaging, for people with no response to initial treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">de Almeida et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Zandian et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Masterson et al, 2015</a>]. The suggestion to refer after a 3-week period with no improvement is based on expert opinion in a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Zandian et al, 2014</a>]. A US clinical practice guideline advises referral of people with incomplete facial recovery 3 months after initial symptom onset on the grounds that most people will have recovered completely within this time [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>].  </li><li>Referral of people with atypical features allows specialist testing and exclusion of conditions other than Bell's palsy that cause facial weakness [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Stew and Williams, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Zandian et al, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Phan et al, 2016</a>]. </li><li>Referral to a plastic surgical facial reanimation service may be an option for some people with long-standing residual symptoms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Stew and Williams, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Glass and Tzafetta, 2014a</a>]. In some cases, electromyography and motor nerve conduction studies can help specialists make decisions on treatment and whether surgical management is indicated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Zandian et al, 2014</a>]. Rehabilitative and reconstructive procedures such as tendon and muscle transfer and nerve substitutions can improve facial functionality and appearance, resulting in improved quality of life and social function [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Eviston et al, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Phan et al, 2016</a>]. </li></ul></li></ul><h5>Referral to an ophthalmologist </h5><ul><li>Referral if a person has eye symptoms is recommended in both a US clinical practice guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>]<strong> </strong>and a review article [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Phan et al, 2016</a>]. Eye complications can be potentially serious, including corneal ulceration and vision loss, but can be prevented with good eye care [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>]. <ul><li>Botulinum injections can help to temporarily improve eyelid closure<strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>]. Surgical management (for example, eyelid weights or muscle transfer) may be considered to avoid irreversible damage to the eye if symptoms continue [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Albers and Tamang, 2014</a>].  </li></ul></li></ul><h5>Referral for support or counselling</h5><ul><li>Depression and reduced quality of life may occur as a result of facial dysfunction and this may be helped by support and counselling [<a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Baugh et al, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bells-palsy/references/\">Phan et al, 2016</a>]. </li></ul><!-- end field b0addfe0-6ea7-438b-b794-74820e347897 --><!-- end item 256e1f8a-88b2-4f59-8b52-6b7e31d009c7 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}